Anders HJ - Search Results

1

The mineralocorticoid receptor in chronic kidney disease.

Barrera-Chimal J, Jaisser F, Anders HJ. Barrera-Chimal J, et al. Among authors: anders hj. Br J Pharmacol. 2022 Jul;179(13):3152-3164. doi: 10.1111/bph.15734. Epub 2021 Dec 28. Br J Pharmacol. 2022. PMID: 34786690 Free article. Review.

2

NOD-like and Toll-like receptors or inflammasomes contribute to kidney disease in a canonical and a non-canonical manner.

Anders HJ, Lech M. Anders HJ, et al. Kidney Int. 2013 Aug;84(2):225-8. doi: 10.1038/ki.2013.122. Kidney Int. 2013. PMID: 23903414 Free article.

3

Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease.

Ma Q, Steiger S, Anders HJ. Ma Q, et al. Among authors: anders hj. Physiol Rep. 2017 Apr;5(7):e13228. doi: 10.14814/phy2.13228. Physiol Rep. 2017. PMID: 28364032 Free PMC article.

4

Chronic kidney disease.

Romagnani P, Remuzzi G, Glassock R, Levin A, Jager KJ, Tonelli M, Massy Z, Wanner C, Anders HJ. Romagnani P, et al. Among authors: anders hj. Nat Rev Dis Primers. 2017 Nov 23;3:17088. doi: 10.1038/nrdp.2017.88. Nat Rev Dis Primers. 2017. PMID: 29168475 Review.

5

CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease.

Anders HJ, Huber TB, Isermann B, Schiffer M. Anders HJ, et al. Nat Rev Nephrol. 2018 Jun;14(6):361-377. doi: 10.1038/s41581-018-0001-y. Nat Rev Nephrol. 2018. PMID: 29654297 Review.

6

The gut flora modulates intestinal barrier integrity but not progression of chronic kidney disease in hyperoxaluria-related nephrocalcinosis.

Konrad L, Andersen K, Kesper MS, Kumar SV, Mulay SR, Anders HJ. Konrad L, et al. Among authors: anders hj. Nephrol Dial Transplant. 2020 Jan 1;35(1):86-97. doi: 10.1093/ndt/gfz080. Nephrol Dial Transplant. 2020. PMID: 31081025

7

Interleukin-1β Inhibition for Chronic Kidney Disease in Obese Mice With Type 2 Diabetes.

Lei Y, Devarapu SK, Motrapu M, Cohen CD, Lindenmeyer MT, Moll S, Kumar SV, Anders HJ. Lei Y, et al. Among authors: anders hj. Front Immunol. 2019 May 29;10:1223. doi: 10.3389/fimmu.2019.01223. eCollection 2019. Front Immunol. 2019. PMID: 31191559 Free PMC article.

8

Intestinal microbiome and fitness in kidney disease.

Meijers B, Evenepoel P, Anders HJ. Meijers B, et al. Among authors: anders hj. Nat Rev Nephrol. 2019 Sep;15(9):531-545. doi: 10.1038/s41581-019-0172-1. Epub 2019 Jun 26. Nat Rev Nephrol. 2019. PMID: 31243394 Review.

9

Drug Testing for Residual Progression of Diabetic Kidney Disease in Mice Beyond Therapy with Metformin, Ramipril, and Empagliflozin.

Motrapu M, Świderska MK, Mesas I, Marschner JA, Lei Y, Martinez Valenzuela L, Fu J, Lee K, Angelotti ML, Antonelli G, Romagnani P, Anders HJ, Anguiano L. Motrapu M, et al. Among authors: anders hj. J Am Soc Nephrol. 2020 Aug;31(8):1729-1745. doi: 10.1681/ASN.2019070703. Epub 2020 Jun 23. J Am Soc Nephrol. 2020. PMID: 32576600 Free PMC article.

10

SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney disease, 'diabetic nephropathy', IgA nephropathy and podocytopathies with FSGS lesions.

Anders HJ, Peired AJ, Romagnani P. Anders HJ, et al. Nephrol Dial Transplant. 2022 Aug 22;37(9):1609-1615. doi: 10.1093/ndt/gfaa329. Nephrol Dial Transplant. 2022. PMID: 33313878

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

462 results

Search Page